689 related articles for article (PubMed ID: 28373135)
1. The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer Prediction.
Distler FA; Radtke JP; Bonekamp D; Kesch C; Schlemmer HP; Wieczorek K; Kirchner M; Pahernik S; Hohenfellner M; Hadaschik BA
J Urol; 2017 Sep; 198(3):575-582. PubMed ID: 28373135
[TBL] [Abstract][Full Text] [Related]
2. Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.
Niu XK; Li J; Das SK; Xiong Y; Yang CB; Peng T
BMC Med Imaging; 2017 Feb; 17(1):11. PubMed ID: 28143433
[TBL] [Abstract][Full Text] [Related]
3. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
4. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30142318
[TBL] [Abstract][Full Text] [Related]
5. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
6. A Single Center Evaluation of the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging against Transperineal Prostate Mapping Biopsy: An Analysis of Men with Benign Histology and Insignificant Cancer following Transrectal Ultrasound Biopsy.
Pal RP; Ahmad R; Trecartan S; Voss J; Ahmed S; Bazo A; Lloyd J; Walton TJ
J Urol; 2018 Aug; 200(2):302-308. PubMed ID: 29477717
[TBL] [Abstract][Full Text] [Related]
7. Risk Stratification of Equivocal Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate.
Ullrich T; Quentin M; Arsov C; Schmaltz AK; Tschischka A; Laqua N; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
J Urol; 2018 Mar; 199(3):691-698. PubMed ID: 28941924
[TBL] [Abstract][Full Text] [Related]
8. Is it Time to Perform Only Magnetic Resonance Imaging Targeted Cores? Our Experience with 1,032 Men Who Underwent Prostate Biopsy.
Pepe P; Garufi A; Priolo GD; Galia A; Fraggetta F; Pennisi M
J Urol; 2018 Oct; 200(4):774-778. PubMed ID: 29679618
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Transrectal Ultrasound Biopsy to Transperineal Template Mapping Biopsies Stratified by Multiparametric Magnetic Resonance Imaging Score in the PROMIS Trial.
Lovegrove CE; Miah S; El-Shater Bosaily A; Bott S; Brown L; Burns-Cox N; Dudderidge T; Freeman A; Henderson A; Hindley R; Kaplan R; Kirkham A; Oldroyd R; Parker C; Persad R; Punwani S; Rosario D; Shergill I; Winkler M; Emberton M; Ahmed HU
J Urol; 2020 Jan; 203(1):100-107. PubMed ID: 31335254
[TBL] [Abstract][Full Text] [Related]
10. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
[TBL] [Abstract][Full Text] [Related]
11. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study.
Thompson JE; Moses D; Shnier R; Brenner P; Delprado W; Ponsky L; Pulbrook M; Böhm M; Haynes AM; Hayen A; Stricker PD
J Urol; 2014 Jul; 192(1):67-74. PubMed ID: 24518762
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcome Following Low Suspicion Multiparametric Prostate Magnetic Resonance Imaging or Benign Magnetic Resonance Imaging Guided Biopsy to Detect Prostate Cancer.
Boesen L; Nørgaard N; Løgager V; Thomsen HS
J Urol; 2017 Aug; 198(2):310-315. PubMed ID: 28235549
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance.
Radtke JP; Kuru TH; Boxler S; Alt CD; Popeneciu IV; Huettenbrink C; Klein T; Steinemann S; Bergstraesser C; Roethke M; Roth W; Schlemmer HP; Hohenfellner M; Hadaschik BA
J Urol; 2015 Jan; 193(1):87-94. PubMed ID: 25079939
[TBL] [Abstract][Full Text] [Related]
14. Which Patients with Negative Magnetic Resonance Imaging Can Safely Avoid Biopsy for Prostate Cancer?
Oishi M; Shin T; Ohe C; Nassiri N; Palmer SL; Aron M; Ashrafi AN; Cacciamani GE; Chen F; Duddalwar V; Stern MC; Ukimura O; Gill IS; Luis de Castro Abreu A
J Urol; 2019 Feb; 201(2):268-276. PubMed ID: 30189186
[TBL] [Abstract][Full Text] [Related]
15. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M
BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389
[TBL] [Abstract][Full Text] [Related]
16. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397
[TBL] [Abstract][Full Text] [Related]
17. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
[TBL] [Abstract][Full Text] [Related]
18. Assessment of free-hand transperineal targeted prostate biopsy using multiparametric magnetic resonance imaging-transrectal ultrasound fusion in Chinese men with prior negative biopsy and elevated prostate-specific antigen.
Lian H; Zhuang J; Wang W; Zhang B; Shi J; Li D; Fu Y; Jiang X; Zhou W; Guo H
BMC Urol; 2017 Jul; 17(1):52. PubMed ID: 28679370
[TBL] [Abstract][Full Text] [Related]
19. Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer.
Rais-Bahrami S; Siddiqui MM; Turkbey B; Stamatakis L; Logan J; Hoang AN; Walton-Diaz A; Vourganti S; Truong H; Kruecker J; Merino MJ; Wood BJ; Choyke PL; Pinto PA
J Urol; 2013 Nov; 190(5):1721-1727. PubMed ID: 23727310
[TBL] [Abstract][Full Text] [Related]
20. Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative Effect.
Perlis N; Al-Kasab T; Ahmad A; Goldberg E; Fadak K; Sayyid R; Finelli A; Kulkarni G; Hamilton R; Zlotta A; Ghai S; Fleshner N
J Urol; 2018 May; 199(5):1182-1187. PubMed ID: 29175542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]